Money Runners

[stockhits]

VSTA’s lead drug candidate, AV-101, is in Phase Ib development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects approximately 1.8 million people in the U.S. alone. To date, we have been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.